Supreme Court Keeps Abortion Pill Available by Mail, Telehealth

For a woman in Port St. Lucie or Jensen Beach navigating an unintended pregnancy, Thursday's Supreme Court order was the difference between a phone call and a plane ticket.

The Supreme Court voted to preserve telehealth access to mifepristone, the most widely used abortion medication in the United States, blocking a federal appeals court ruling that would have banned the drug from being mailed anywhere in the country. The high court's stay — issued around 5:30 p.m. Thursday, roughly 30 minutes past a deadline the justices set for themselves — keeps the status quo in place while a case brought by Louisiana against the Food and Drug Administration works its way through the lower courts.

For Treasure Coast women, that access is direct and immediate. Under the telehealth model, a patient connects with a licensed provider by phone or video. If eligible, she receives a prescription for mifepristone and a second drug, misoprostol, which can be picked up at a local pharmacy or mailed to her home. Florida's six-week abortion ban — among the strictest in the Southeast — has driven many residents toward telehealth providers operating from states where abortion remains legal. One in four abortions nationally now occurs via telemedicine, according to public health data, and medication abortion accounts for the majority of all U.S. abortions since the Supreme Court overturned Roe v. Wade in 2022.

The New Orleans-based U.S. Fifth Circuit Court of Appeals had ruled May 1 that mifepristone could not be mailed — a prohibition that would have applied nationwide, not only in states with abortion bans. Thursday's order stays that ruling.

Justices Samuel Alito and Clarence Thomas dissented publicly. In his written dissent, Alito called the order "unreasoned" and "remarkable," and argued the case was "the perpetration of a scheme to undermine our decision in Dobbs" — the 2022 ruling he authored that eliminated the federal constitutional right to abortion.

A notable absence shaped the proceeding: the FDA, the named defendant in the lawsuit, filed no brief with the justices. The Trump administration's FDA did not respond to the court's request for input — a silence that legal observers said reflected the administration's broader reluctance to take a firm public stance on abortion access. FDA Commissioner Dr. Marty Makary resigned under White House pressure this week. It is unclear whether the mifepristone litigation contributed to his departure.

A coalition of former FDA leaders, who served under both Democratic and Republican presidents, submitted a brief defending the agency's science-based approval process and warning that the appeals court ruling "would upend FDA's gold-standard, science-based drug approval system." The pharmaceutical industry's trade group, PhRMA, filed a similar brief urging the court not to disturb the regulatory framework governing the drug.

If the stay is eventually lifted and the lower court ruling takes effect, providers have said they would shift patients to a higher-dose misoprostol-only protocol — a method researchers describe as equally safe and effective but associated with greater side effects, including nausea and diarrhea.

The underlying case returns to lower federal courts, with no timeline confirmed for a final ruling.

This article was generated with AI assistance using publicly available information. It was reviewed and approved by a human editor before publication. TC Sentinel uses AI writing tools in accordance with FTC guidelines.